Plasmacytoid monocytes (PMs) constitute a rare cell type that was originally described in human lymph nodes based on their plasma cell-like morphology, the expression of CD4, CD31, CD36, CD68 and ...

A patient with a rare, aggressive, blastic plasmacytoid dendritic-cell neoplasm had tumor cells overexpressing BCL2 and had a response with a durable remission to venetoclax, a BCL2 inhibitor.

ABOUT BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) BPDCN is a rare form of blood cancer that has features of both leukemia and lymphoma, ... lymph node involvement, ...

Plasmacytoid dendritic cells can be activated with viral and bacterial DNA via TLR9. Activated pDCs promote generation of both Th1/Th17 cells [46,76,87,92] and Tregs [104,105].

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a type of blood cancer that affects immune system cells. It most often affects the skin but can also involve bone marrow and other cell types.

The FDA has approved Stemline Therapeutics’ tagraxofusp-erzs (Elzonris), the first drug approved to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients ...

ABOUT BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM BPDCN is a rare form of blood cancer that has features of both leukemia and lymphoma, with characteristic skin lesions, lymph node involvement ...

Blastic plasmacytoid dendric cell neoplasm (BPDCN) is a rare, aggressive blood cancer that often involves the bone marrow, skin and, sometimes, lymph nodes. First-in-class antibody-drug conjugate ...

More specifically, plasmacytoid dendritic cells sense SARS-CoV-2 and elicit antiviral protection of lung epithelial cells through Toll-like receptor 7 (TLR7), while recognition of Toll-like ...